Overview
- The multi-year collaboration carries potential payments of up to US$888 million, with Insilico eligible for up to US$32 million in upfront and near-term R&D funding.
- Insilico will use its Pharma.AI platform to identify drug candidates that meet predefined criteria, while Servier shares R&D costs and assumes clinical validation, regulatory work, and global commercialization.
- The agreement focuses on difficult oncology targets and formalizes a division of responsibilities that pairs AI-driven discovery with large-pharma development capabilities.
- The announcement follows Insilico’s late-December listing in Hong Kong, where the company raised HK$2.28 billion (about US$293 million) in its IPO.
- Insilico highlights an active oncology pipeline, including ISM6331 and ISM3412 in global Phase I trials, and says its platform has yielded 20 preclinical candidates from 2021 to 2024 with 12–18 month discovery timelines.